
Lab11 Therapeutics LLC Profile last edited on: 7/20/22
CAGE: 808J7
UEI: Z4RTHLMK8YJ3
Business Identifier: Broad spectrum anti-viral drugs Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
223 Bedford Avenue
Brooklyn, NY 11211
Brooklyn, NY 11211
(917) 576-4742 |
info@lab11therapeutics.org |
www.lab11therapeutics.org |
Location: Single
Congr. District: 12
County: Kings
Congr. District: 12
County: Kings
Public Profile
Identified as working in the space of Broad Spectrum Anti-Virals, Lab11 Therapeutics LLC is identified as a startup biotech company using human genetics as a lead towards therapy development using the latest in technology to design, test, validate and improve drugs. Developing drugs that would allow to be prepared for novel viral pandemics, with a strong J&J association in New York and Washington DC, the firm is working on two programs developing host-mediated broad spectrum antivirals: 1) small-molecule broad spectrum, and 2) mRNA mediated delivery of host antiviral effectors, serving as broad spectrum antivirals. Broad spectrum antivirals do not exist.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2021 | 1 | NIH | $255,932 | |
Project Title: Transient Gene Therapy as Broad Spectrum Antiviral |
Key People / Management
Dusan Bogunovic -- CEO and President
Company News
There are no news available.